175 related articles for article (PubMed ID: 28784680)
1. N-Acylated Derivatives of Sulfamethoxazole Block Chlamydia Fatty Acid Synthesis and Interact with FabF.
Mojica SA; Salin O; Bastidas RJ; Sunduru N; Hedenström M; Andersson CD; Núñez-Otero C; Engström P; Valdivia RH; Elofsson M; Gylfe Å
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784680
[TBL] [Abstract][Full Text] [Related]
2. Type II fatty acid synthesis is essential for the replication of Chlamydia trachomatis.
Yao J; Abdelrahman YM; Robertson RM; Cox JV; Belland RJ; White SW; Rock CO
J Biol Chem; 2014 Aug; 289(32):22365-76. PubMed ID: 24958721
[TBL] [Abstract][Full Text] [Related]
3. Clinical Relevance of Type II Fatty Acid Synthesis Bypass in Staphylococcus aureus.
Gloux K; Guillemet M; Soler C; Morvan C; Halpern D; Pourcel C; Vu Thien H; Lamberet G; Gruss A
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193654
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the Mitochondrion-Fatty Acid Axis for the Metabolic Reprogramming of Chlamydia trachomatis during Treatment with β-Lactam Antimicrobials.
Shima K; Kaufhold I; Eder T; Käding N; Schmidt N; Ogunsulire IM; Deenen R; Köhrer K; Friedrich D; Isay SE; Grebien F; Klinger M; Richer BC; Günther UL; Deepe GS; Rattei T; Rupp J
mBio; 2021 Mar; 12(2):. PubMed ID: 33785629
[TBL] [Abstract][Full Text] [Related]
5. N-acylated derivatives of sulfamethoxazole and sulfafurazole inhibit intracellular growth of Chlamydia trachomatis.
Marwaha S; Uvell H; Salin O; Lindgren AE; Silver J; Elofsson M; Gylfe A
Antimicrob Agents Chemother; 2014 May; 58(5):2968-71. PubMed ID: 24566180
[TBL] [Abstract][Full Text] [Related]
6. Structural insights into bacterial resistance to cerulenin.
Trajtenberg F; Altabe S; Larrieux N; Ficarra F; de Mendoza D; Buschiazzo A; Schujman GE
FEBS J; 2014 May; 281(10):2324-38. PubMed ID: 24641521
[TBL] [Abstract][Full Text] [Related]
7. Proteomic signature of fatty acid biosynthesis inhibition available for in vivo mechanism-of-action studies.
Wenzel M; Patra M; Albrecht D; Chen DY; Nicolaou KC; Metzler-Nolte N; Bandow JE
Antimicrob Agents Chemother; 2011 Jun; 55(6):2590-6. PubMed ID: 21383089
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of self-resistance in the platensimycin- and platencin-producing Streptomyces platensis MA7327 and MA7339 strains.
Peterson RM; Huang T; Rudolf JD; Smanski MJ; Shen B
Chem Biol; 2014 Mar; 21(3):389-397. PubMed ID: 24560608
[TBL] [Abstract][Full Text] [Related]
9. Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials.
Morvan C; Halpern D; Kénanian G; Hays C; Anba-Mondoloni J; Brinster S; Kennedy S; Trieu-Cuot P; Poyart C; Lamberet G; Gloux K; Gruss A
Nat Commun; 2016 Oct; 7():12944. PubMed ID: 27703138
[TBL] [Abstract][Full Text] [Related]
10. Platensimycin and platencin: promising antibiotics for future application in human medicine.
Martens E; Demain AL
J Antibiot (Tokyo); 2011 Nov; 64(11):705-10. PubMed ID: 21915133
[TBL] [Abstract][Full Text] [Related]
11. Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis.
Xia M; Suchland RJ; Carswell JA; Van Duzer J; Buxton DK; Brown K; Rothstein DM; Stamm WE
Antimicrob Agents Chemother; 2005 Sep; 49(9):3974-6. PubMed ID: 16127086
[TBL] [Abstract][Full Text] [Related]
12. How bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics.
Yao J; Rock CO
J Biol Chem; 2015 Mar; 290(10):5940-6. PubMed ID: 25648887
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel FabF ligands inspired by platensimycin by integrating structure-based design with diversity-oriented synthetic accessibility.
Fisher M; Basak R; Kalverda AP; Fishwick CW; Turnbull WB; Nelson A
Org Biomol Chem; 2014 Jan; 12(3):486-94. PubMed ID: 24276506
[TBL] [Abstract][Full Text] [Related]
14. Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy.
Ondeyka JG; Zink DL; Young K; Painter R; Kodali S; Galgoci A; Collado J; Tormo JR; Basilio A; Vicente F; Wang J; Singh SB
J Nat Prod; 2006 Mar; 69(3):377-80. PubMed ID: 16562839
[TBL] [Abstract][Full Text] [Related]
15. Platensimycin: a promising antimicrobial targeting fatty acid synthesis.
Manallack DT; Crosby IT; Khakham Y; Capuano B
Curr Med Chem; 2008; 15(7):705-10. PubMed ID: 18336284
[TBL] [Abstract][Full Text] [Related]
16. Thiazolino 2-Pyridone Amide Inhibitors of Chlamydia trachomatis Infectivity.
Good JA; Silver J; Núñez-Otero C; Bahnan W; Krishnan KS; Salin O; Engström P; Svensson R; Artursson P; Gylfe Å; Bergström S; Almqvist F
J Med Chem; 2016 Mar; 59(5):2094-108. PubMed ID: 26849778
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in inhibitors of bacterial fatty acid synthesis type II (FASII) system enzymes as potential antibacterial agents.
Wang Y; Ma S
ChemMedChem; 2013 Oct; 8(10):1589-608. PubMed ID: 23894064
[TBL] [Abstract][Full Text] [Related]
18. The antimicrobial susceptibility of Chlamydia trachomatis in cell culture.
Ridgway GL; Owen JM; Oriel JD
Br J Vener Dis; 1978 Apr; 54(2):103-6. PubMed ID: 638716
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial Resistance Screening in Chlamydia trachomatis by Optimized McCoy Cell Culture System and Direct qPCR-Based Monitoring of Chlamydial Growth.
Meštrović T; Virok DP; Ljubin-Sternak S; Raffai T; Burián K; Vraneš J
Methods Mol Biol; 2019; 2042():33-43. PubMed ID: 31385269
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Chlamydia trachomatis Growth During the Last Decade: A Mini-Review.
Serradji N; Vu TH; Kim H; Panyam J; Verbeke P
Mini Rev Med Chem; 2018; 18(16):1363-1372. PubMed ID: 29692244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
